ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1896

Lupus Keratinocytes Exhibit Skewed Interferon Responses and Dysregulation of a Novel Regulator of Interferon Signaling

Alex Tsoi1, Grace Hile2, Celine C. Berthier3, Mrinal Sarkar4, Tamra J. Reed5, Ranjitha Uppala4, Matthew Patrick4, Kalpana Raja4, Xianying Xing6, Kevin He2, Johann Gudjonsson4 and Michelle Kahlenberg7, 1Departments of Dermatology and Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, 2University of Michigan, Ann Arbor, MI, 3Nephrology, Division of Nephrology, University of Michigan Medical Center, Ann Arbor, MI, 4Dermatology, University of Michigan, Ann Arbor, MI, 5Internal Medicine, Rheumatology, University of Michigan, Ann Arbor, MI, 6Dermatology, University of Michigan, University of Michigan, Ann Arbor, MI, 7Internal Medicine, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Cutaneous lupus erythematosus, Interferons and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: 4M108 ACR Abstract: SLE–Etiology & Pathogenesis I (1893–1898)

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease in which 70% of patients experience disfiguring skin inflammation (grouped under the rubric of cutaneous lupus erythematosus (CLE)). Studies have revealed that interferons (IFNs) are important mediators for SLE and CLE, but the mechanisms by which IFNs lead to disease are still poorly understood. We and others have previously identified increased type I IFN expression in non-lesional SLE keratinocytes, but whether alterations in response to IFNs also contribute to disease is unknown. We thus aimed to investigate IFN responses in SLE vs. control keratinocytes and to identify mechanisms by which differential regulation may occur.

Methods: Age and gender-matched control (n=7) and SLE (n=7) keratinocytes were isolated from non-lesional, non-sun exposed 6mm punch skin biopsies from the upper thigh and used at passage 3. All patients gave written, informed consent and were treated according to the Declaration of Helsinki. These keratinocytes were treated with or without 5 ng/mL of IFNα, IFNβ, IFNκ, and IFNγ for 6 hours followed by RNA isolation and RNA-sequencing. In-depth analysis of the interferon response was conducted. PITX1 expression in normal and CLE lesional skin was evaluated by immunohistochemistry. Knockdown of PITX1 was used to examine IFN gene expression in the absence of PITX1.

Results: A significant hypersensitive response to IFNs was identified in lupus keratinocytes including genes (IFIH1, STAT1, and IRF7) encompassed in SLE susceptibility loci. In particular, 273 genes in SLE keratinocytes demonstrated a higher effect size (p=5.8×10-32); these genes were termed lupus sensitive interferon (LSI) responses. Importantly, 50 LSI response genes were significantly enriched among the dysregulated genes in CLE lesions (p=1.8×10-41), confirming their in vivo relevance. Binding sites for the transcription factor PITX1 were significantly enriched (p=2×10-4) in the LSI genes, suggesting a role for PITX1 in regulation of IFN responses. Indeed, PITX1 expression was increased in CLE lesions, and knockdown of PITX1 expression in N/TERT keratinocytes significantly abrogated interferon response gene expression after type I IFN, but not TNFα stimulation.

Conclusion: SLE patients exhibit increased interferon signatures in their skin secondary to increased production and a robust, skewed IFN response that is regulated by PITX1. Targeting of these exaggerated pathways may prove to be beneficial to prevent and treat hyperinflammatory responses in SLE skin.


Disclosure: A. Tsoi, None; G. Hile, None; C. C. Berthier, None; M. Sarkar, None; T. J. Reed, None; R. Uppala, None; M. Patrick, None; K. Raja, None; X. Xing, None; K. He, None; J. Gudjonsson, None; M. Kahlenberg, None.

To cite this abstract in AMA style:

Tsoi A, Hile G, Berthier CC, Sarkar M, Reed TJ, Uppala R, Patrick M, Raja K, Xing X, He K, Gudjonsson J, Kahlenberg M. Lupus Keratinocytes Exhibit Skewed Interferon Responses and Dysregulation of a Novel Regulator of Interferon Signaling [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/lupus-keratinocytes-exhibit-skewed-interferon-responses-and-dysregulation-of-a-novel-regulator-of-interferon-signaling/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/lupus-keratinocytes-exhibit-skewed-interferon-responses-and-dysregulation-of-a-novel-regulator-of-interferon-signaling/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology